StockData
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. (ALLO) stock

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.70−0.05 (-6.48%)

Close on Nov 18, 2026Market cap $240.43MP/E –Yield 0.00%

Allogene Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Allogene Therapeutics

Allogene Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Allogene Therapeutics figures

See a number that looks wrong?